# ImmunityBio, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ImmunityBio, Inc.). ## Overview ImmunityBio, Inc. is a U.S. biotechnology company developing and commercializing immunotherapies that activate both the innate and adaptive immune systems. Its core platform centers on ANKTIVA® (nogapendekin alfa inbakicept) and a broader Cancer BioShield portfolio that includes NK-cell therapies, adenovirus-vectored vaccines, and other immunomodulators aimed at cancer and infectious disease. ## Products & services • ANKTIVA® (nogapendekin alfa inbakicept) • Cancer BioShield immunotherapy platform • Off-the-shelf and autologous NK-cell therapies • Adenovirus-vectored vaccine programs • Commercial product distribution and market access services • Cell lines, bioreactors, and related consumables - **Commercial immunotherapy** (55%) — Approved and marketed oncology immunotherapy centered on ANKTIVA for commercial use. - **Clinical-stage pipeline** (25%) — Development programs including NK-cell therapies, vaccines, and other immunomodulators. - **Licensing and IP programs** (10%) — Non-exclusive license agreements and licensed technology monetization. - **Bioprocessing products** (10%) — Sale of bioreactors and related consumables used in research and manufacturing. - ANKTIVA® (IL-15 superagonist antibody-cytokine fusion protein) - Cancer BioShield platform for cancer and infectious disease immunotherapy - Off-the-shelf and autologous NK-cell-based therapies - Adenovirus-vectored vaccine programs - Commercial distribution of approved product through specialty channels - Cell lines, bioreactors, and related consumables ## Customers ImmunityBio sells primarily to healthcare providers and institutions that administer oncology therapies, including clinics, hospitals, infusion centers, and government entities. Its commercial product is distributed through specialty distributors and a specialty pharmacy provider, while earlier-stage revenue has also come from licensing partners and buyers of bioprocessing equipment and consumables. - **Oncology treatment centers** (primary) — Clinics, hospitals, and infusion centers that buy ANKTIVA to treat eligible cancer patients and need specialty distribution support. - **Specialty pharmacy and distributors** (primary) — Channel partners that handle stocking and delivery of the approved product into care settings. - **Government and institutional buyers** (secondary) — Public-sector and institutional purchasers that access the commercial product through contracted specialty channels. - **Licensing counterparties** (secondary) — Partners that license cell lines, know-how, or other intellectual property and generate non-product revenue. - **Bioprocessing customers** (emerging) — Customers buying bioreactors and consumables for research, development, or manufacturing use. - Urology and oncology clinics treating patients with approved ANKTIVA use - Hospitals and infusion centers administering specialty biologics - Government entities and public health systems purchasing through specialty channels - Licensing partners using cell lines and related intellectual property - Research and manufacturing customers buying bioreactors and consumables ## Geography The company is headquartered in the United States and its current commercial buildout is centered there, including manufacturing, distribution, and initial sales infrastructure. Management also describes active global expansion efforts, with clinical trial applications for ResQ201A submitted or planned in the EU, UK, Canada, and Asia, which broadens regulatory and execution risk beyond the U.S. - United States is the core market for approved ANKTIVA commercialization - Dunkirk, New York is a key manufacturing and scale-up location - EU and UK are targeted for clinical expansion of ResQ201A - Canada and Asia are planned next-step trial and market expansion regions - Global expansion increases regulatory and supply-chain complexity ## Strategy ImmunityBio is building a commercial oncology franchise around ANKTIVA while advancing a broader universal Cancer BioShield platform. Near term, the company is focused on scaling U.S. sales, expanding market access, and using its manufacturing footprint and third-party CMOs to support supply and future product launches. - **Grow ANKTIVA commercial adoption** (short-term) — The approved product is the main near-term revenue driver and validates the platform. - **Strengthen manufacturing resilience** (medium-term) — Commercial supply and future pipeline launches depend on reliable, scalable production. - **Advance pipeline beyond ANKTIVA** (medium-term) — Long-term value depends on converting the broader platform into additional approved products. - Scale ANKTIVA commercialization in urology and adjacent oncology settings - Expand specialty distribution and market access to improve product uptake - Advance Cancer BioShield pipeline programs into later-stage development - Use Dunkirk and third-party CMOs to diversify manufacturing capacity - Pursue global clinical expansion for ResQ201A and related programs ## Risks The company remains highly dependent on a single approved product while most of its pipeline is still clinical-stage, so execution on commercialization and development is critical. It also faces financing, manufacturing, regulatory, and intellectual-property risks that are typical for biotech but amplified by its need to scale a new commercial platform and fund global trials. - **Dependence on a single approved product** [high] — The company has one commercial product and a broad clinical pipeline, so any setback in ANKTIVA uptake would materially affect revenue and credibility. - **Need for additional financing** [high] — Commercialization, manufacturing buildout, and clinical trials require substantial cash before the business reaches durable scale. - **Manufacturing and supply constraints** [high] — Shelf life, comparability, and facility obligations can affect product availability and delay changes in production sources. - **Regulatory and clinical development risk** [high] — Pipeline programs require successful trials and approvals in multiple jurisdictions, which may not be achieved on schedule or at all. - **Intellectual property and licensing obligations** [medium] — The company relies on licensed technology and may owe milestones and royalties that reduce economics. - **Cybersecurity and third-party operational risk** [medium] — Clinical, manufacturing, and shared-service systems depend on external vendors and are exposed to cyberattacks and outages. - Single approved product creates concentration risk if ANKTIVA adoption slows - Additional financing may be needed to fund trials, launch, and manufacturing - Manufacturing scale-up and supply shelf-life issues could disrupt sales - Regulatory delays or adverse trial results could set back pipeline value - Patent, license, and royalty obligations can constrain economics and flexibility - Cybersecurity and data breaches could disrupt operations and clinical programs ## Accounting Revenue recognition is a key judgment area because product sales are recorded when control transfers, net of rebates, chargebacks, discounts, and returns. Investors should also watch estimates for contingent milestones, revenue-interest obligations, and lease-related commitments tied to the Dunkirk facility, since these can materially affect reported liabilities, cash needs, and future expense recognition. - **Revenue recognition and sales deductions** — Can materially affect quarterly revenue and gross-to-net trends - **Contingent milestone and royalty obligations** — Affects liabilities, cash flow, and long-term product economics - **Lease and facility commitments** — Creates significant future cash obligations and execution risk - **Estimates and assumptions in a clinical-stage biotech** — Can cause meaningful period-to-period changes in reported results - Product revenue is recognized at delivery, net of rebates and chargebacks - Sales deductions and returns require estimates that can move reported revenue - Milestone and royalty obligations affect liabilities and future cash outflows - Dunkirk lease and operating commitments create large off-balance-sheet-like obligations - Clinical and commercial estimates can change with trial progress and supply assumptions --- *Last updated: 2026-04-28T20:17:02.581163+00:00*